Edward Roberts Jr.

Array ( [id] => 19345220 [patent_doc_number] => 20240254183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => MEMBRANE-BOUND IL-12 FOR CELLULAR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/612579 [patent_app_country] => US [patent_app_date] => 2024-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19526749 [patent_doc_number] => 20240350651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => THERAPEUTIC MOLECULES THAT BIND TO LAG3 AND PD1 [patent_app_type] => utility [patent_app_number] => 18/604076 [patent_app_country] => US [patent_app_date] => 2024-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27592 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18604076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403646 [patent_doc_number] => 20240287157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => DARIC INTERLEUKIN RECEPTORS [patent_app_type] => utility [patent_app_number] => 18/595641 [patent_app_country] => US [patent_app_date] => 2024-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35211 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18595641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19770040 [patent_doc_number] => 20250051466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => Methods of Treating Multiple Myeloma with Bispecific Anti-BCMA x Anti-CD3 Antibodies [patent_app_type] => utility [patent_app_number] => 18/429887 [patent_app_country] => US [patent_app_date] => 2024-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47197 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18429887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380990 [patent_doc_number] => 20240270860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/399071 [patent_app_country] => US [patent_app_date] => 2023-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66198 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18399071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20301208 [patent_doc_number] => 12447178 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptors [patent_app_type] => utility [patent_app_number] => 18/395996 [patent_app_country] => US [patent_app_date] => 2023-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 15025 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18395996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125762 [patent_doc_number] => 20240131115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => IL-15-BASED MOLECULES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/394409 [patent_app_country] => US [patent_app_date] => 2023-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30619 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18394409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19512122 [patent_doc_number] => 20240343808 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES [patent_app_type] => utility [patent_app_number] => 18/392954 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 103008 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18392954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19049295 [patent_doc_number] => 20240091264 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS [patent_app_type] => utility [patent_app_number] => 18/524799 [patent_app_country] => US [patent_app_date] => 2023-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18524799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19249042 [patent_doc_number] => 20240200029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => NKP30 RECEPTOR TARGETED THERAPEUTICS [patent_app_type] => utility [patent_app_number] => 18/513960 [patent_app_country] => US [patent_app_date] => 2023-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29466 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18513960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050954 [patent_doc_number] => 20240092923 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => ANTI-CD30L ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/510511 [patent_app_country] => US [patent_app_date] => 2023-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99180 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -89 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18510511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157773 [patent_doc_number] => 20240150480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => BINDING MOLECULES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/508346 [patent_app_country] => US [patent_app_date] => 2023-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18508346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19187840 [patent_doc_number] => 20240166753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN FOR ACTIVATION OF NATURAL KILLER CELLS AND THERAPEUTIC USES THEREOF TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 18/482629 [patent_app_country] => US [patent_app_date] => 2023-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25032 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18482629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050948 [patent_doc_number] => 20240092917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/477113 [patent_app_country] => US [patent_app_date] => 2023-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19418525 [patent_doc_number] => 20240294648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => MANAbodies AND METHODS OF USING [patent_app_type] => utility [patent_app_number] => 18/473695 [patent_app_country] => US [patent_app_date] => 2023-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18473695 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050953 [patent_doc_number] => 20240092922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => ANTI-TNFRSF9 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/465115 [patent_app_country] => US [patent_app_date] => 2023-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38052 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18465115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19142228 [patent_doc_number] => 20240141057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => ANTI-DR5 FAMILY ANTIBODIES, BISPECIFIC OR MULTIVALENT ANTI-DR5 FAMILY ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/461910 [patent_app_country] => US [patent_app_date] => 2023-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18461910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19961643 [patent_doc_number] => 12331127 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-17 [patent_title] => Therapeutic uses of anti-GITR antibodies [patent_app_type] => utility [patent_app_number] => 18/461760 [patent_app_country] => US [patent_app_date] => 2023-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 46 [patent_no_of_words] => 28738 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18461760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986410 [patent_doc_number] => 20240058379 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => USE OF TLR AGONIST AND ANTI-CD47 AGENT TO ENHANCE PHAGOCYTOSIS OF CANCER CELLS [patent_app_type] => utility [patent_app_number] => 18/458037 [patent_app_country] => US [patent_app_date] => 2023-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18458037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19172522 [patent_doc_number] => 20240158496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => MULTIFUNCTIONAL BTLA EXTRACELLULAR DOMAIN CO-INHIBITORY MOIETY TRAPS TO MODULATE IMMUNE TOLERANCE [patent_app_type] => utility [patent_app_number] => 18/238385 [patent_app_country] => US [patent_app_date] => 2023-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35247 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18238385 [rel_patent_id] =>[rel_patent_doc_number] =>)